<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic evaluation of polycystic ovary syndrome in adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic evaluation of polycystic ovary syndrome in adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnostic evaluation of polycystic ovary syndrome in adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Natalie Shaw, MD, MMSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Rosenfield, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell E Geffner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elise DeVore Berlan, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H929873085"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Polycystic ovary syndrome (PCOS) is the most common cause of infertility in women [<a href="#rid1">1</a>], frequently becomes manifest during adolescence, and is primarily characterized by ovulatory dysfunction and androgen excess (hyperandrogenism). The syndrome is heterogeneous clinically and biochemically. The diagnosis of PCOS has lifelong implications with increased risk for metabolic syndrome, type 2 diabetes mellitus, and possibly cardiovascular disease and endometrial carcinoma. PCOS should be considered in any adolescent female presenting with a chief complaint of hirsutism, treatment-resistant acne, menstrual irregularity, acanthosis nigricans, and/or obesity.</p><p>The diagnostic evaluation of an adolescent with suspected PCOS is described here. Other aspects of PCOS in adolescents are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5853.html" rel="external">"Treatment of polycystic ovary syndrome in adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5799.html" rel="external">"Etiology and pathophysiology of polycystic ovary syndrome in adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H768364214"><span class="h1">INDICATIONS FOR EVALUATION</span><span class="headingEndMark"> — </span>An evaluation for PCOS is recommended for adolescent females with one or more of the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>An abnormal degree of hirsutism or a hirsutism equivalent, such as inflammatory acne vulgaris, that is poorly responsive to topical therapies or oral antibiotics if this is accompanied by menstrual abnormality</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focal hirsutism (localized areas of excessive sexual hair growth) if this is accompanied by menstrual abnormality</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Menstrual abnormality (persistent amenorrhea or oligomenorrhea, or excessive uterine bleeding)  (<a class="graphic graphic_table graphicRef93199" href="/d/graphic/93199.html" rel="external">table 1</a>)</p><p></p><p>Acanthosis nigricans is a manifestation of insulin resistance and may be the presenting complaint of PCOS [<a href="#rid2">2</a>] (see  <a class="medical medical_review" href="/d/html/5799.html" rel="external">"Etiology and pathophysiology of polycystic ovary syndrome in adolescents"</a>). Examination will usually reveal some of the above classical symptoms or signs, but occasionally these may not develop for some time. Thus, in the absence of risk factors for PCOS, such as a family history of PCOS, type 2 diabetes mellitus, or premature balding in males [<a href="#rid3">3</a>], one may choose to defer a workup of these latter patients for PCOS and instead observe them for the emergence of clinical evidence of PCOS over time. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H768363647"><span class="h1">EVALUATION OVERVIEW</span><span class="headingEndMark"> — </span>We suggest a stepwise approach to the evaluation that addresses the diagnostic criteria  (<a class="graphic graphic_table graphicRef107842" href="/d/graphic/107842.html" rel="external">table 2</a>) [<a href="#rid4">4</a>]. This approach is first outlined here and then detailed in the sections below  (<a class="graphic graphic_algorithm graphicRef117557" href="/d/graphic/117557.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Basic evaluation</strong> – The evaluation begins with a focused clinical evaluation for symptoms and signs suggestive of PCOS: menstrual irregularity, hirsutism (or hirsutism equivalents, such as acne), and acanthosis nigricans. This is followed by laboratory testing for hyperandrogenemia  (<a class="graphic graphic_algorithm graphicRef117557" href="/d/graphic/117557.html" rel="external">algorithm 1</a>). (See <a class="local">'History and physical examination'</a> below and <a class="local">'Screening tests to detect common causes of abnormal menses'</a> below.)</p><p></p><p class="bulletIndent1">Patients with elevated testosterone should be further evaluated with a screening panel of laboratory tests to rule out other common non-PCOS causes of hyperandrogenemia  (<a class="graphic graphic_algorithm graphicRef85781" href="/d/graphic/85781.html" rel="external">algorithm 2</a>) [<a href="#rid5">5</a>]. This evaluation excludes the vast majority of disorders that mimic PCOS.</p><p></p><p class="bulletIndent1">Ultrasonography of the ovaries and adrenal glands is often part of the first-line workup of hyperandrogenic females, primarily to evaluate for rare tumors of these organs. Some other experts reserve the ultrasonographic screening for those patients with atypical features suggestive of virilization, such as rapidly progressive hirsutism, clitoromegaly, or hirsutism or menstrual abnormality that fails to respond to therapy, and/or when there are marked elevations of testosterone and/or dehydroepiandrosterone sulfate. (See <a class="local">'Screening tests to exclude common non-PCOS causes of hyperandrogenemia'</a> below.)</p><p></p><p class="bulletIndent1">Some experts order most of these screening tests during the first visit. This approach is a simple and economical use of time for most patients but is not always practical because measurement of serum 17-hydroxyprogesterone (17OHP) and other steroids requires early-morning sampling to be highly discriminatory in detecting nonclassic congenital adrenal hyperplasia (NCCAH). Some other experts perform the tests serially or select among the tests based on clinical symptoms and signs that raise concerns for a particular disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Demonstration of persistent hyperandrogenism in a patient with a persistently abnormal degree of menstrual irregularity fulfills the diagnostic criteria for PCOS, provided that the endocrine screening tests are negative for disorders that mimic PCOS. This minimalist approach is approximately 99 percent specific for PCOS in young people and meets international consensus criteria for the diagnosis of PCOS in adolescents [<a href="#rid6">6-9</a>]. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">Lack of hyperandrogenemia effectively rules out the diagnosis of PCOS in most adolescents. However, the ovarian hyperandrogenism of PCOS may not become demonstrable until a few years after menarche [<a href="#rid10">10,11</a>]. Thus, young patients with a menstrual abnormality should be followed, and the diagnosis of PCOS should not be dismissed until their menses normalize and androgen levels remain normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further endocrine evaluation</strong> – The basic evaluation described above does not exclude rare virilizing disorders  (<a class="graphic graphic_table graphicRef91894" href="/d/graphic/91894.html" rel="external">table 3</a>) [<a href="#rid12">12-14</a>]. In the presence of concern about the possibility of a rare virilizing disorder, such as a tumor or rare congenital disorder, a more comprehensive evaluation is needed  (<a class="graphic graphic_algorithm graphicRef85781" href="/d/graphic/85781.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef65682" href="/d/graphic/65682.html" rel="external">algorithm 3</a>). These tests also help to exclude the possibility that a mild PCOS picture is due to obesity and would be expected to respond to simple weight-control measures alone. This approach is consistent with the hirsutism clinical practice guidelines from the Endocrine Society [<a href="#rid14">14</a>]. (See <a class="local">'Further evaluation by endocrinology subspecialists for rare disorders mimicking PCOS'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation after the diagnosis of PCOS</strong> – Patients diagnosed with PCOS should have additional evaluations for glucose intolerance and other features of the metabolic syndrome, particularly if they are obese. Primary relatives of PCOS patients may also benefit from screening for these disorders. (See <a class="local">'Additional evaluation of PCOS patients'</a> below and <a class="local">'Evaluation of family members'</a> below.)</p><p></p><p class="headingAnchor" id="H768363654"><span class="h1">BASIC DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H768363661"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The evaluation starts with a thorough assessment of the clinical symptoms and signs suggestive of hyperandrogenism and anovulation (ie, for disorders that mimic PCOS  (<a class="graphic graphic_algorithm graphicRef117557" href="/d/graphic/117557.html" rel="external">algorithm 1</a>)). The cutaneous manifestations of hyperandrogenism (particularly hirsutism and acne, which occur in approximately three-quarters of PCOS cases) provide clinical evidence of hyperandrogenism. An abnormal menstrual pattern constitutes evidence of oligo-anovulation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hirsutism</strong> – The degree and distribution of sexual hair growth should be documented using the Ferriman-Gallwey score  (<a class="graphic graphic_figure graphicRef66629" href="/d/graphic/66629.html" rel="external">figure 1</a>). An adult level of sexual hair growth seems to ordinarily be reached in females by two years after menarche, though data are sparse [<a href="#rid7">7,15</a>]. Hirsutism should be interpreted in the context of norms for the patient's ethnicity. Absence of hirsutism does not preclude hyperandrogenemia. Moderate or severe hirsutism (hirsutism score &gt;15) constitutes clinical evidence of hyperandrogenism in an adolescent [<a href="#rid6">6-8</a>]. The history should specifically explore whether the patient shaves excess hair or uses depilatory agents, which may obscure the physical findings, and whether the patient is taking medications that cause hirsutism (eg, anabolic-androgenic steroids, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproic acid</a>). (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Hirsutism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acne</strong> – The degree of acne should be evaluated in the context of the patient's gynecologic age. The possibility of hyperandrogenism is suggested by moderate or severe inflammatory acne (&gt;10 lesions in any area, eg, face, chest, back  (<a class="graphic graphic_table graphicRef107843" href="/d/graphic/107843.html" rel="external">table 4</a>)) through the perimenarchal years or acne that is persistent and poorly responsive to topical or oral antibiotic dermatologic therapy [<a href="#rid6">6-8</a>]. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Acne'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Menses</strong> – The age of menarche and subsequent menstrual patterns should be described and interpreted in the context of the patient's gynecologic age. The types of menstrual dysfunction that suggest abnormal degrees of anovulation in adolescence are detailed in the table  (<a class="graphic graphic_table graphicRef93199" href="/d/graphic/93199.html" rel="external">table 1</a>) [<a href="#rid4">4</a>]. A menstrual pattern that is outside of these bounds for two years (or one year with supporting evidence for PCOS) can be considered a "persistent" abnormality and fulfills one of the two criteria for the diagnosis of PCOS [<a href="#rid4">4,6-8</a>]. Note that normal menstrual regularity does not necessarily mean that ovulatory function is normal. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Anovulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity and acanthosis nigricans</strong> – Obesity or acanthosis nigricans are often the initial complaint, though not necessarily the only PCOS symptoms or signs elucidated upon review of systems and examination. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Assessment should include a history of medications that may either mask the symptoms (eg, oral contraceptives and topical or systemic acne medications) or cause the symptoms (eg, anabolic-androgenic steroids, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproic acid</a> for epilepsy). Assessment should also include evaluation for features that suggest a hyperandrogenic disorder other than PCOS, including virilization (eg, rapidly progressive hirsutism), galactorrhea, Cushingoid or acromegaloid changes, evidence of thyroid dysfunction, or a family history of hyperandrogenic disorders  (<a class="graphic graphic_algorithm graphicRef117557" href="/d/graphic/117557.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H2767484881"><span class="h2">Testing for hyperandrogenemia</span><span class="headingEndMark"> — </span>Testing for total testosterone or preferably free testosterone should be included in the initial evaluation of a patient with clinical symptoms and signs suggesting PCOS  (<a class="graphic graphic_algorithm graphicRef117557" href="/d/graphic/117557.html" rel="external">algorithm 1</a>). However, these tests are only reliable if they are performed using a highly sensitive, accurate, and specific assay. If combined estrogen-progestin oral contraceptives (COCs) were previously started, they should be withdrawn for two to three months before screening for PCOS because they suppress testosterone production. Current or recent use of systemic glucocorticoids also may moderately suppress total and free testosterone. Testing methods and interpretation are discussed below.</p><p>If a reliable testosterone assay is not available, the presence of moderate or severe hirsutism is approximately 85 percent specific for hyperandrogenemia and may be used as clinical evidence for hyperandrogenism  (<a class="graphic graphic_table graphicRef107842" href="/d/graphic/107842.html" rel="external">table 2</a>) [<a href="#rid6">6-8</a>]. Mild hirsutism is a less reliable criterion for androgen excess because only approximately one-half of patients with mild hirsutism have hyperandrogenemia, three-quarters of whom have a coincident menstrual abnormality [<a href="#rid14">14</a>].</p><p>For patients with severe or rapidly progressive hyperandrogenism, measurement of dehydroepiandrosterone sulfate (DHEAS) should be included in the initial evaluation to screen for a virilizing adrenal tumor.</p><p>Patients who have clinical features consistent with PCOS, but have an initial normal total testosterone level, should have further measurement of an early-morning (8 AM) serum free testosterone level. (See <a class="local">'Considerations for testosterone assays'</a> below.)</p><p class="headingAnchor" id="H3274966355"><span class="h3">Considerations for testosterone assays</span><span class="headingEndMark"> — </span>Persistent serum total or free testosterone elevation above adult norms is the best single test for hyperandrogenemia in postmenarchal females [<a href="#rid6">6-8,14</a>].</p><p>The choice between testing for the presence of hyperandrogenemia with an assay of total or free testosterone depends on assay availability [<a href="#rid14">14</a>]. If a reliable method for measuring serum free (or bioavailable) testosterone is available, and cost is not a significant issue, this test is the preferred choice for initial evaluation.</p><p>There are many pitfalls in testosterone assays at the low levels found in patients with PCOS, and reliable testosterone assays are sometimes not available to clinicians.</p><p class="bulletIndent1"><span class="glyph">●</span>Free testosterone – An elevation of serum (or plasma) free testosterone is the single most sensitive test to establish the presence of hyperandrogenemia [<a href="#rid6">6,14,16-18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The serum free testosterone concentration is approximately 50 percent more sensitive for the detection of hyperandrogenemia than the total testosterone concentration. This is because PCOS is characterized by low levels of SHBG, which is the main determinant of the fraction of serum testosterone that is weakly bound to albumin and the fraction that is free from protein binding, and thus ultimately bioactive [<a href="#rid19">19,20</a>]. Consequently, the combination of an upper-normal total testosterone and a lower-normal SHBG yields a high free testosterone concentration. SHBG production by the liver is raised by estrogen and hyperthyroidism, and it is suppressed in the settings of hyperandrogenemia and/or hyperinsulinemia (seen with obesity-induced insulin resistance) [<a href="#rid21">21</a>]. Although the low SHBG in obese individuals has been attributed to hyperinsulinemia [<a href="#rid22">22</a>], evidence suggests that excess glucose and fructose intake themselves and inflammatory cytokines mediate the SHBG reduction in patients with obesity [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The only reliable methods report free testosterone that is calculated as the product of the serum total testosterone and a function of binding to SHBG [<a href="#rid14">14,24,25</a>]. The most accurate methods calculate percent free testosterone as determined by equilibrium dialysis or, alternatively, as calculated from the SHBG concentration [<a href="#rid26">26</a>]. An alternative reliable method is to calculate "bioavailable testosterone" by determining the percent of serum testosterone not precipitated with globulins by ammonium sulfate (the supernatant includes both the fraction free and that weakly bound to albumin, the latter being bioactive to the extent that it dissociates to free in a given tissue space dependent upon the local interstitial albumin concentration) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Direct assays of the serum free testosterone concentration are inaccurate and should be avoided [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total testosterone – Liquid chromatography-mass spectrometry is the preferred method for measuring total testosterone [<a href="#rid27">27</a>]. Where this technology is not available, high-quality postchromatographic radioimmunoassays yield comparable results and are the method of choice [<a href="#rid8">8,25</a>]. Nevertheless, results by the best available assays vary by an average of approximately 6 to 26 percent [<a href="#rid13">13,28</a>]. The automated assays that are used to measure serum total testosterone in some laboratories are not suitable to accurately measure levels in females [<a href="#rid16">16,29</a>].</p><p></p><p class="headingAnchor" id="H513431063"><span class="h3">Interpretation of testosterone levels</span><span class="headingEndMark"> — </span>The normal upper limit for serum total testosterone in adult cisgender women and transgender men who have not started testosterone is approximately 40 to 60 ng/dL (1.4 to 2.1 nmol/L) when using most validated assays [<a href="#rid16">16-18</a>]. The adult norm is also the appropriate reference range for adolescents [<a href="#rid6">6,7</a>]. Most patients with PCOS have serum testosterone concentrations of 29 to 150 ng/dL (1 to 5.2 nmol/L). A total testosterone &gt;150 ng/dL (5.1 nmol/L) increases the likelihood of a virilizing ovarian or adrenal neoplasm: this cut-off has approximately 90 percent sensitivity and 80 percent specificity for androgen-producing tumors in adults [<a href="#rid30">30</a>]. However, it is not the most reliable method for detecting the most common virilizing disorder presenting in adolescence, nonclassic congenital adrenal hyperplasia (NCCAH) secondary to 21-hydroxylase deficiency, as discussed below. (See <a class="local">'Endocrine screening panel'</a> below.)</p><p>For practical purposes, an elevated serum total and/or free testosterone at any time of day provides evidence of hyperandrogenism in an anovulatory cycle. However, a normal level in the afternoon does not exclude hyperandrogenemia. This is partly because serum testosterone undergoes episodic changes of approximately twofold (trough-to-peak). It is also partly because norms are standardized for early morning (8 AM) on days 4 through 10 of the menstrual cycle (follicular phase) in people with regular cycles as normal testosterone levels fall 10 percent from 8 AM to 4 PM and double during midcycle [<a href="#rid25">25,31,32</a>].</p><p>COCs interfere with the assessment of androgens. The estrogen-progestin content suppresses gonadotropins, elevates SHBG, and directly inhibits steroidogenic enzymes such as 3-beta-hydroxysteroid dehydrogenase. They normalize androgens in PCOS and also have been reported to normalize androgens in some virilizing tumors [<a href="#rid33">33</a>]. After discontinuing COCs, healthy people may transiently have a slightly high total testosterone level, but a normal free testosterone level because SHBG turnover is slower than testosterone turnover.</p><p class="headingAnchor" id="H629214742"><span class="h2">Screening tests to detect common causes of abnormal menses</span><span class="headingEndMark"> — </span>Most patients presenting for evaluation of hyperandrogenism have a menstrual abnormality for which screening for other causes of anovulatory disorders is indicated  (<a class="graphic graphic_algorithm graphicRef117557" href="/d/graphic/117557.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/104218.html" rel="external">"Causes of primary amenorrhea"</a> and  <a class="medical medical_review" href="/d/html/104135.html" rel="external">"Epidemiology and causes of secondary amenorrhea"</a>.)</p><p>Initial screening for patients with a menstrual abnormality should include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-human chorionic gonadotropin (beta-hCG)</strong> – Pregnancy should be excluded in all anovulatory patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic disease screening</strong> – Complete blood count, erythrocyte sedimentation rate or C-reactive protein (CRP), comprehensive metabolic panel, and celiac-specific antibodies (tissue transglutaminase along with total immunoglobulin A [IgA]) to screen for chronic diseases that can cause anovulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follicle-stimulating hormone (FSH) and luteinizing hormone (LH)</strong> – Slightly elevated LH and slightly low FSH are characteristic of typical PCOS, but LH is also affected by body mass index (BMI) and phase of menstrual cycle: In people with PCOS, LH is inversely proportional to BMI [<a href="#rid34">34,35</a>]. Markedly elevated FSH suggests primary hypogonadism, whereas low LH and FSH indicate secondary hypogonadism (eg, a pituitary tumor or a functional or genetic form of hypogonadotropic hypogonadism). Glucocorticoids suppress gonadotropin levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolactin</strong> – Hyperprolactinemia is a cause of gonadotropin deficiency. It is not accompanied by galactorrhea if the gonadotropin deficiency is profound, because of concurrent estrogen deficiency [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid-stimulating hormone (TSH)</strong> – Normal serum TSH levels are ordinarily adequate to rule out thyroid dysfunction, which causes menstrual dysfunction. Hypothyroidism may cause confusion with hyperandrogenism by causing coarsening of hair (which can be mistaken for hirsutism [<a href="#rid7">7</a>]), lowering SHBG, and, in severe cases, causing multicystic ovaries. Hyperthyroidism may confound the diagnosis of hyperandrogenism by raising SHBG, which may elevate the total testosterone. Note that mildly elevated levels of TSH are often found in obese individuals, but this is a consequence rather than a cause of the obesity and is reversible if weight loss can be achieved. (See  <a class="medical medical_review" href="/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence"</a>.)</p><p></p><p class="headingAnchor" id="H768363685"><span class="h2">Screening tests to exclude common non-PCOS causes of hyperandrogenemia</span><span class="headingEndMark"> — </span>If serum testosterone and/or free testosterone is elevated, the next step is to exclude most non-PCOS causes of hyperandrogenemia. Adult and adolescent specialty society guidelines for the diagnosis of PCOS differ slightly as to which tests should be routinely obtained versus which tests should be considered only in those patients with suggestive clinical features of disorders that may mimic PCOS [<a href="#rid6">6,37-40</a>]. Consequently, expert practice varies regarding the extent and timing of further laboratory evaluation. Some experts perform a simple screening battery of endocrine tests and ultrasonography at this stage  (<a class="graphic graphic_algorithm graphicRef85781" href="/d/graphic/85781.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef91894" href="/d/graphic/91894.html" rel="external">table 3</a>). Other experts perform these tests in selected patients with atypical features, such as virilization (to rule out virilizing neoplasm), central obesity (to rule out Cushing syndrome), or acromegaloid features.</p><p class="headingAnchor" id="H2557581445"><span class="h3">Endocrine screening panel</span><span class="headingEndMark"> — </span>In patients with PCOS, the following endocrine studies will be normal. An abnormal result for any of these tests suggests another cause of hyperandrogenism (see  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a>) and should be further evaluated as suggested in the linked topic reviews.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early-morning 17-hydroxyprogesterone (17OHP)</strong> – An 8 AM 17OHP level should be measured in all females with hyperandrogenism [<a href="#rid14">14</a>]. It is a good screening test for NCCAH secondary to 21-hydroxylase deficiency when performed under properly controlled circumstances:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early-morning sampling is critical to detect the 17OHP elevation of NCCAH because it wanes rapidly thereafter due to the diurnal variation of adrenal steroid secretion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It is important to obtain the screening sample when the patient is amenorrheic or within the first 10 days after the start of a menstrual cycle in regularly cycling patients because 17OHP rises during the preovulatory and luteal phases of the cycle. A 17OHP value of &gt;170 ng/dL (5.1 nmol/L) is suggestive of NCCAH. This cutoff displayed approximately 95 percent sensitivity and 90 percent specificity in detecting NCCAH, with the main confounders being PCOS (&gt;20 percent of patients with PCOS have elevated baseline 17OHP concentrations, as do some with tumoral hyperandrogenism) and recent ovulation [<a href="#rid25">25,41,42</a>].</p><p></p><p class="bulletIndent2">An abnormal screening test is not diagnostic but requires a cosyntropin (ACTH) stimulation test to confirm the diagnosis of CAH, unless the basal 17OHP level is &gt;1000 ng/dL (30 nmol/L). (See <a class="local">'Further evaluation by endocrinology subspecialists for rare disorders mimicking PCOS'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We also measure serum progesterone at the same time as the 17OHP measurement to rule out the possibility that the patient has unexpectedly ovulated (which occurs in approximately 10 percent of oligo-amenorrheic PCOS patients) and is unknowingly being tested in the luteal phase of her cycle. The luteal phase is documented by a serum progesterone &gt;175 ng/dL in adolescents (5.3 nmol/L) [<a href="#rid43">43</a>] or &gt;200 ng/dL (6 nmol/L) in adults [<a href="#rid44">44</a>] and can be accompanied by 17OHP levels up to 500 ng/dL (15 nmol/L) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In those patients with known congenital adrenal hyperplasia (CAH) that is complicated by PCOS (see  <a class="medical medical_review" href="/d/html/5799.html" rel="external">"Etiology and pathophysiology of polycystic ovary syndrome in adolescents", section on 'Congenital virilization'</a>), full glucocorticoid replacement treatment will suppress the baseline 17OHP level to normal, but androgen levels will remain slightly elevated. (See  <a class="medical medical_review" href="/d/html/5799.html" rel="external">"Etiology and pathophysiology of polycystic ovary syndrome in adolescents", section on 'Congenital virilization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other androgens</strong> – DHEAS is included primarily to screen for an adrenal tumor. It is a marker for adrenal hyperandrogenism and has little diurnal variation. While the most common cause of DHEAS elevation is the functional adrenal hyperandrogenism of PCOS [<a href="#rid45">45</a>], the main purpose of measuring DHEAS levels is to rapidly identify an unusual virilizing adrenal disorder, such as an adrenal tumor. Females with a virilizing tumor usually present with a rapid onset of virilizing features, and DHEAS levels are often, but not necessarily, markedly elevated (&gt;700 mcg/dL, 19 micromol/L) if the tumor is of adrenal origin. CAH seldom causes severe DHEAS elevation [<a href="#rid45">45</a>]. However, in a substantial minority of patients with virilizing tumors, the symptoms are indolent in onset and mimic PCOS in presentation (see  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/123.html" rel="external">"Adrenal hyperandrogenism"</a>). COCs have equivocal effects on the DHEAS level. (See  <a class="medical medical_review" href="/d/html/5798.html" rel="external">"Physiology and clinical manifestations of normal adrenarche"</a>.)</p><p></p><p class="bulletIndent1">The measurement of other androgens, such as androstenedione, is ordinarily of little diagnostic utility, except in situations of diagnostic uncertainty [<a href="#rid14">14</a>]; however, some experts prefer to combine assay of total testosterone with that of androstenedione in place of free testosterone [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">Serum levels of 11-beta-hydroxytestosterone and 11-ketotestosterone have been reported to be elevated in PCOS [<a href="#rid47">47,48</a>]. These are recognized bioactive adrenal androgens; the former is secreted by the adrenal cortex, and the latter is produced peripherally from adrenal-secreted 11-beta-hydroxyandrostenedione [<a href="#rid49">49</a>]. Whether they are of more diagnostic utility than DHEAS levels remains to be demonstrated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolactin</strong> – Prolactin should be measured at this stage if it was not done in the initial panel of screening tests for abnormal menses. Androgen excess occurs in 40 percent of people with hyperprolactinemia due to multiple effects of prolactin excess on adrenal androgen production and androgen metabolism, and the great majority (approximately 85 percent) of these people have galactorrhea [<a href="#rid50">50</a>]. The combination of hirsutism, galactorrhea, and amenorrhea is sometimes described as Forbes-Albright syndrome. Prolactin elevation is unusual in PCOS itself, occurring in less than 1 percent of subjects. A marginal elevation (eg, to &lt;25 ng/mL) in the absence of specific clinical evidence does not necessitate a prolactinoma workup [<a href="#rid40">40,51,52</a>]. Serum prolactin values more than 25 ng/mL usually have an identifiable cause rather than PCOS [<a href="#rid51">51</a>]. Estrogenic medications increase prolactin secretion, but the amount of estrogen in low-dose COCs generally does not. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum cortisol</strong> – Serum cortisol is an optional test that many experts perform only for hyperandrogenic patients with central obesity. The purpose is to screen for endogenous Cushing syndrome (due to adrenal hyperplasia or adrenal tumors), which is sometimes associated with adrenal overproduction of testosterone. Although the normal range for serum cortisol is wide (5 to 25 mcg/dL), a serum cortisol concentration of &lt;10 mcg/dL (276 nmol/L) is reassuring evidence against endogenous Cushing syndrome. A midday or afternoon sample is more optimal for this screening than an early-morning sample. Patients with markedly elevated serum cortisol levels or those with clinical features suggestive of Cushing syndrome warrant further evaluation (eg, with 24-hour urine collection for free cortisol and creatinine). Estrogen raises total serum cortisol levels by increasing cortisol-binding globulin, but low-dose COCs do not generally cause falsely abnormal results. (See  <a class="medical medical_review" href="/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin-like growth factor 1 (IGF-1)</strong> – This is an optional test that many experts perform only for hyperandrogenic patients with gigantism or acromegaloid features. Elevated IGF-1 distinguishes growth hormone (GH) excess as a cause of hyperandrogenism [<a href="#rid53">53</a>] from the pseudoacromegalic hyperandrogenism of severe insulin resistance syndromes [<a href="#rid54">54</a>]. GH excess usually can be identified by clinical symptoms (gigantism in growing children or acromegaly after epiphyseal fusion) in teenagers and adults. However, the author has seen acromegaly first present with PCOS-like symptoms. The oral estrogen of COCs may lower IGF-1 levels sufficiently to obscure the diagnosis of acromegaly. (See  <a class="medical medical_review" href="/d/html/6635.html" rel="external">"Diagnosis of acromegaly"</a>.)</p><p></p><p class="headingAnchor" id="H1904866936"><span class="h3">Ultrasonography</span><span class="headingEndMark"> — </span>The primary purpose of ultrasonography in the hyperandrogenemic adolescent is to exclude causes other than PCOS. A secondary benefit is to identify the few individuals with very large ovaries, for whom it simply provides further evidence of PCOS severity and diagnostic specificity, as discussed below. In PCOS, ultrasound may also demonstrate a characteristic homogeneous and thick endometrium. Ultrasonography is neither recommended nor required for the <strong>diagnosis</strong> of PCOS in adolescents, because the high frequency of polycystic-appearing ovaries in normal females in this age group makes this an unreliable criterion for the diagnosis of PCOS [<a href="#rid55">55</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>The role of ultrasonography in the differential diagnosis of PCOS</strong> – Practice varies as to the indications for ultrasonography in adolescent females with confirmed hyperandrogenemia, since ultrasonography is not recommended for the diagnosis of PCOS. Most experts perform ultrasonography only for selected patients with features that are atypical for PCOS, such as very high testosterone levels (eg, &gt;150 ng/dL), clitoromegaly, rapidly progressive hirsutism, or poor response to treatment [<a href="#rid56">56</a>]. Among a series of 96 adolescents with PCOS diagnosed by Rotterdam criteria [<a href="#rid39">39</a>], only 2.1 percent had an actionable ultrasound finding unrelated to PCOS and these were also unrelated to hyperandrogenism [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1">The primary purpose of ultrasonography is to screen for the rare but serious ovarian tumor  (<a class="graphic graphic_algorithm graphicRef85781" href="/d/graphic/85781.html" rel="external">algorithm 2</a>). In addition, other pelvic pathology, including an ovotesticular disorder of sex development and the functional hyperandrogenism of pregnancy, may be detected by ultrasonography. On rare occasions, ultrasonography has been insensitive in detecting a virilizing ovarian tumor in adults [<a href="#rid58">58,59</a>]. It may also reveal a virilizing adrenocortical tumor and, if there is reason to suspect this, more specialized imaging studies are indicated (see  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>). Patients who have an ultrasound that shows an ovarian tumor or other explanation for hyperandrogenism should be referred for further evaluation and treatment of the underlying disorder. Otherwise, hyperandrogenic females need further endocrine studies irrespective of whether the ovaries are polycystic, as discussed in the section above. (See <a class="local">'Endocrine screening panel'</a> above.)</p><p></p><p class="bulletIndent1">Ultrasonography also provides the opportunity for patient reassurance and education. For many people, the diagnosis of ovarian "cysts" raises a concern about tumors, so it is reassuring to know that a tumor has been ruled out by the ultrasound. The clinician can explain to the PCOS patient with a polycystic ovary that these are numerous small egg sacs that are not ovulating properly. Conversely, if a polycystic ovary is not visualized in a PCOS patient, the clinician can explain that the ovarian dysfunction is "too mild to be seen on the ultrasound."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrasonographic criteria for polycystic ovary morphology (PCOM)</strong> – The ultrasonographic finding of PCOM is supportive of a diagnosis of PCOS, but it is not included in the diagnostic criteria for PCOS in adolescents [<a href="#rid6">6-9</a>]. This is because of uncertainties about the definitive criteria for PCOM in this age group  (<a class="graphic graphic_diagnosticimage graphicRef138271" href="/d/graphic/138271.html" rel="external">image 1</a>). However, we suggest careful follow-up of adolescents with PCOM because the presence of clear PCOM, in combination with symptomatic hyperandrogenism in the absence of anovulatory symptoms, poses a risk for PCOS in an adolescent [<a href="#rid60">60</a>]. In adults, these same features would meet a somewhat nonspecific PCOS criterion. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Adults'</a>.)</p><p></p><p class="bulletIndent1">International consensus criteria for adults define PCOM on the basis of either excessive ovarian volume or follicle number (or both) in the absence of a dominant-sized follicle (&gt;1 mL) or a corpus luteum, as evaluated by transvaginal ultrasonography ≥8 years after menarche [<a href="#rid9">9,39,61</a>] (see  <a class="medical medical_review" href="/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults", section on 'Transvaginal ultrasound'</a>). On the one hand, there is a high prevalence of PCOM in the most clinically severe PCOS cases [<a href="#rid60">60</a>]. On the other hand, PCOM is a common normal variant in asymptomatic people that may predict a slightly longer period of fertility [<a href="#rid60">60</a>]. Furthermore, it has become apparent that these criteria are problematic in young adults because they naturally have slightly larger ovaries [<a href="#rid62">62</a>], and the newer high-definition vaginal imaging techniques show that small antral follicle counts up to 24 are normal [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adult PCOM criteria are especially problematic when applied to adolescents [<a href="#rid6">6,7</a>]. For one thing, antral follicle count cannot necessarily be accurately defined by abdominal ultrasonography and vaginal ultrasonography is not appropriate or tolerated by some adolescents [<a href="#rid63">63,64</a>]. Three-dimensional ultrasound data indicate that over one-half of eumenorrheic adolescents meet Rotterdam criteria for antral follicle count [<a href="#rid65">65</a>]. Additionally, two-dimensional ultrasound studies indicate that ovarian volume is slightly larger in adolescents than in adults, though actual volumes vary considerably among studies [<a href="#rid66">66,67</a>]. Consequently, one-quarter to one-half of normal adolescents meet Rotterdam adult criteria for PCOM [<a href="#rid64">64,65,68</a>]. These data suggest that PCOM by adult criteria constitutes a transient stage of normal ovarian development, peaking in prevalence at 14 to 17 years of age.</p><p></p><p class="bulletIndent1">In 2015, an international consensus group tentatively proposed using a (mean) ovarian volume &gt;12 mL to constitute PCOM in adolescence [<a href="#rid6">6</a>]. However, this threshold may be too low since a single ovarian volume up to 14 mL was the median of three ultrasonographic studies of normal adolescents [<a href="#rid60">60</a>]. Subsequent larger ultrasound studies have not clarified the matter: Normal ovarian volumes continue to differ considerably among studies [<a href="#rid60">60,64-67</a>].</p><p></p><p class="bulletIndent1">These ultrasound data are generally supported by two magnetic resonance imaging (MRI) studies of well-characterized, healthy, normally menstruating adolescents and adolescents with PCOS, totaling approximately 40 per group [<a href="#rid69">69,70</a>]. They reported that the upper normal cutoff for small antral follicle counts is 17 to 25 per ovary and that the upper normal for the size of a single ovary is 14 mL.</p><p></p><p class="headingAnchor" id="H3211128357"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>PCOS can be diagnosed in a patient with a <strong>persistently</strong> abnormal uterine bleeding pattern and evidence of hyperandrogenism  (<a class="graphic graphic_table graphicRef107842" href="/d/graphic/107842.html" rel="external">table 2</a>) after exclusion of non-PCOS causes of hyperandrogenemia  (<a class="graphic graphic_table graphicRef91894" href="/d/graphic/91894.html" rel="external">table 3</a>). Most clinical guidelines recommend screening for nonclassic congenital adrenal hyperplasia (NCCAH), Cushing syndrome, prolactin excess, thyroid dysfunction, and acromegaly. However, the guidelines vary as to which tests are recommended for universal screening and which are recommended only for patients with symptoms suggestive of one of these disorders. These guidelines are based on expert opinion. Therefore, the actual range of practice varies considerably among expert clinicians in this field.</p><p></p><p>It is also best to confirm the <strong>persistence</strong> of hyperandrogenism in order to avoid labeling as PCOS those adolescents who have transient hyperandrogenemia due to physiologic adolescent anovulation [<a href="#rid6">6</a>] (see  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a>). Approximately one-quarter of adolescents with an abnormal degree of menstrual irregularity will have an elevated androgen level but no clinical manifestations of hyperandrogenism, and neither the hyperandrogenemia nor the menstrual abnormality will persist. In the absence of clinical signs of hyperandrogenism (eg, hirsutism or moderate-to-severe acne), a diagnosis of PCOS is not warranted in an adolescent with anovulatory symptoms and an elevated androgen level without other clinical manifestations of PCOS, unless both of these features are documented to persist for two years [<a href="#rid6">6,7</a>]. On the other hand, there is some evidence that the coexistence of hirsutism with hyperandrogenemia indicates that the hyperandrogenemia is persistent and, in combination with a menstrual disorder, permits the diagnosis of PCOS in mid-adolescence [<a href="#rid2">2</a>].</p><p>Adolescents with PCOS or with features of PCOS that do not fulfill diagnostic criteria should be followed to determine that hyperandrogenemia and symptoms persist since data are limited on the natural history of adolescent PCOS. The diagnosis of PCOS should not be fully dismissed until menses normalize and androgen levels remain persistently normal.</p><p class="headingAnchor" id="H768363709"><span class="h1">FURTHER EVALUATION BY ENDOCRINOLOGY SUBSPECIALISTS FOR RARE DISORDERS MIMICKING PCOS</span><span class="headingEndMark"> — </span>Some endocrinologists perform additional testing in hyperandrogenemic patients to detect disorders that mimic PCOS and would go undetected by the above basic screening approach. These disorders include the approximately 1 percent or less who have a rare virilizing disorder that may be encountered no more than a few times in an endocrinologist's career  (<a class="graphic graphic_table graphicRef91894" href="/d/graphic/91894.html" rel="external">table 3</a>), and the 8 percent in whom simple obesity may account for a mild PCOS picture in the absence of ovarian androgenic dysfunction [<a href="#rid13">13</a>]. This diagnostic approach is consistent with that recommended by hirsutism guidelines from the Endocrine Society for evaluation of hirsute women with hyperandrogenemia [<a href="#rid14">14</a>], but the cost-effectiveness is unknown. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a>.)</p><p>Our suggested approach to a more comprehensive diagnostic endocrine evaluation  (<a class="graphic graphic_algorithm graphicRef65682" href="/d/graphic/65682.html" rel="external">algorithm 3</a>) is typically performed only in selected patients during an evaluation by a subspecialist (eg, a pediatric or reproductive endocrinologist). This evaluation may be particularly helpful in patients with atypical features, such as virilization (eg, rapidly progressive hirsutism), unexplained congenital or familial hyperandrogenism, or unresponsiveness to standard therapy. Our approach augments the initial evaluation by starting with a <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> androgen-suppression test (DAST) to distinguish an adrenocorticotropic hormone (ACTH)-dependent adrenal source of androgen excess from other sources of androgen  (<a class="graphic graphic_algorithm graphicRef65682" href="/d/graphic/65682.html" rel="external">algorithm 3</a>) [<a href="#rid12">12</a>]. If indicated by these tests or atypical clinical or laboratory findings, further workup may also include specialized adrenal imaging studies, such as a computed tomography (CT) scan [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Other'</a> and  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p class="headingAnchor" id="H49641701"><span class="h2">Dexamethasone androgen-suppression test</span><span class="headingEndMark"> — </span>The responses of androgens (testosterone and dehydroepiandrosterone sulfate [DHEAS]) and glucocorticoids to <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> suppression are the primary outcome measures to establish the underlying source of hyperandrogenism  (<a class="graphic graphic_algorithm graphicRef65682" href="/d/graphic/65682.html" rel="external">algorithm 3</a>). Normal responses in the University of Chicago laboratory are given in the algorithm legend.</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline levels of the steroid intermediates 17-hydroxypregnenolone (17OHP), 11-deoxycortisol, and/or androstenedione are very elevated in rare forms of congenital adrenal hyperplasia (CAH) and some virilizing tumors. Baseline 24-hour urine glucocorticoids (ie, free cortisol and 17-alpha-hydroxycorticosteroids) with urine creatinine (to ascertain completeness of the specimen) are helpful for the unusual case of Cushing syndrome and the rare cases of glucocorticoid resistance and cortisone reductase deficiency. The latter is characterized by elevated urinary 17-alpha-hydroxycorticosteroid excretion that is comprised predominantly of cortisone rather than cortisol metabolites [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A four-day DAST is the definitive form of <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> suppression testing for the differential diagnosis of hyperandrogenic disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The DAST is interpreted as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If testosterone excess is <strong>not</strong> suppressed by <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a>, but cortisol and DHEAS <strong>are</strong> suppressed normally, the diagnosis of PCOS is virtually assured. However, virilizing tumors and adrenal rests must still be considered in the presence of suggestive clinical factors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <strong>neither</strong> androgen (testosterone and DHEAS) excess <strong>nor</strong> glucocorticoids are suppressed normally by <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a>, then disorders other than PCOS must be considered, such as Cushing syndrome, adrenal tumors, and glucocorticoid resistance (or the dexamethasone was not taken properly). If the levels of androgens suggest an adrenal tumor, further imaging, such as a CT scan, is indicated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <strong>both</strong> androgens (testosterone and DHEAS) <strong>and</strong> glucocorticoids are suppressed normally, an ovarian source for androgen is unlikely, so further evaluation for adrenal disorders with a cosyntropin (ACTH) test for CAH and other rare disorders is indicated.</p><p></p><p class="headingAnchor" id="H49641708"><span class="h2">Cosyntropin (ACTH) stimulation test</span><span class="headingEndMark"> — </span>The responses of steroid intermediates on the pathway to cortisol and androgens distinguish adrenal steroidogenic disorders that mimic PCOS  (<a class="graphic graphic_algorithm graphicRef65682" href="/d/graphic/65682.html" rel="external">algorithm 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>The cosyntropin (ACTH) stimulation test (using a 250 mcg dose, with samples drawn 30 to 60 minutes later) is interpreted as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 17OHP value &gt;1000 ng/dL (30 nmol/L) is highly suggestive, and &gt;1500 ng/dL is definitive, for the 21-hydroxylase deficiency form of nonclassic congenital adrenal hyperplasia (NCCAH) [<a href="#rid72">72</a>]. Intermediate 17OHP levels (1000 to 1500 ng/dL) require genetic confirmation to make a definitive diagnosis of NCCAH [<a href="#rid73">73,74</a>]. (See  <a class="medical medical_review" href="/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mildly elevated responses of 17-hydroxypregnenolone and DHEA are characteristic of the primary functional adrenal hyperandrogenism of PCOS and are often confused with nonclassic 3-beta-hydroxysteroid dehydrogenase deficiency (3-beta-HSD) [<a href="#rid75">75</a>]. Nonclassic 3-beta-HSD is a consideration only if the 17-hydroxypregnenolone response to ACTH is &gt;10 standard deviation (SD) above the normal mean (ie, &gt;4500 ng/dL [150 nmol/L]) [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5799.html" rel="external">"Etiology and pathophysiology of polycystic ovary syndrome in adolescents", section on 'Functional adrenal hyperandrogenism'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonclassic 11-beta-hydroxylase deficiency is a rare form of CAH that may mimic PCOS [<a href="#rid77">77</a>]. Only an 11-deoxycortisol response to ACTH &gt;5 times above the upper limit of normal (&gt;4000 ng/dL/116 nmol/L) has been shown to be specific for detection of pathogenic variants. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a>.)</p><p></p><p>If both the DAST and the <a class="drug drug_pediatric" data-topicid="13183" href="/d/drug information/13183.html" rel="external">ACTH stimulation test</a> are normal, obesity or idiopathic hyperandrogenism is most likely. The most common cause of this may be the atypical PCOS of obesity [<a href="#rid13">13</a>] (see  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a>). The rare possibility of cortisone reductase deficiency should be considered on the basis of the clinical picture. (See  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests"</a> and  <a class="medical medical_review" href="/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults"</a>.)</p><p class="headingAnchor" id="H1457054800"><span class="h2">Ancillary tests</span></p><p class="bulletIndent1"><span class="glyph">●</span>Serum levels of anti-müllerian hormone (AMH) are mildly increased in subjects with polycystic ovary morphology (PCOM; a category that includes both normal adolescents and PCOS subjects) [<a href="#rid68">68,78,79</a>], while AMH elevations of twofold or more above the upper normal limit are highly specific for PCOS [<a href="#rid78">78</a>]. However, elevated serum AMH in adolescence has been reported to be of no additive value to oligomenorrhea in predicting adult PCOS [<a href="#rid80">80</a>]. AMH is a product of the granulosa cells of small growing follicles that normally restrains follicular growth and sex steroid secretion [<a href="#rid81">81,82</a>]; thus, it acts as an intraovarian paracrine gatekeeper to control the recruitment of resting primordial follicles into the growth phase [<a href="#rid68">68,78,79</a>]. Androgen excess in the ovary stimulates primordial follicle growth, causing an increase in antral follicle count that contributes to PCOM. Thus, AMH levels are independently related, on the one hand, to the size of the follicle pool ("follicle reserve" [<a href="#rid78">78,83</a>]) and PCOM (for which AMH has been suggested as a surrogate for ultrasonographic criteria to define PCOM) and, on the other hand, to hyperandrogenism. (See  <a class="medical medical_review" href="/d/html/5799.html" rel="external">"Etiology and pathophysiology of polycystic ovary syndrome in adolescents", section on 'Primary functional ovarian hyperandrogenism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gonadotropin-releasing hormone (GnRH) agonist test – In patients with PCOS, administration of a GnRH agonist induces a rapid hyperresponsive elevation of 17OHP without evidence of a steroidogenic block. The steroid pattern in response to the GnRH agonist distinguishes PCOS from other causes of hyperandrogenic states, particularly rare hyperandrogenic disorders of steroidogenesis, such as nonclassic 3-beta-hydroxysteroid dehydrogenase deficiency. The test is performed by administering <a class="drug drug_pediatric" data-topicid="12545" href="/d/drug information/12545.html" rel="external">leuprolide</a> acetate 10 mcg/kg subcutaneously and measuring steroid levels 20 to 24 hours later; the test can be performed in conjunction with <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> administration (as part of the DAST described above) to suppress coincidental adrenal secretion that might interfere in the interpretation [<a href="#rid84">84,85</a>]. This test may facilitate the early diagnosis of PCOS in adolescents [<a href="#rid2">2</a>]. It also helps to determine if mild PCOS is simply due to obesity, which is suggested when hyperandrogenemia is mild, ovarian morphology is normal, and serum luteinizing hormone, AMH, and DHEAS are not elevated [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on '3-beta-hydroxysteroid dehydrogenase type 2 deficiency'</a>.)</p><p></p><p class="headingAnchor" id="H768363734"><span class="h1">ADDITIONAL EVALUATION OF PCOS PATIENTS</span><span class="headingEndMark"> — </span>Once a diagnosis of PCOS has been established, it is important to discuss the potential long-term sequelae and required interventions for the disorder. These include the need for ongoing lifestyle management, as well as formal emotional support and counseling, and the possibility of future infertility and/or endometrial carcinoma [<a href="#rid86">86</a>]. Additionally, PCOS is a risk factor for early development of type 2 diabetes mellitus, dyslipidemia, hypertension, hepatic steatosis, and sleep-disordered breathing [<a href="#rid87">87,88</a>]. Patients should also be evaluated for quality-of-life issues. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Manifestations of insulin resistance'</a> and  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Psychological issues'</a>.)</p><p>We advise screening for type 2 diabetes mellitus in adolescents with PCOS and obesity, or other risk factors for diabetes mellitus. At the least, a fasting plasma glucose or hemoglobin A1c should be measured. However, an oral glucose tolerance test (OGTT) is preferable because it provides the most sensitive and specific measure of glucose tolerance (see  <a class="medical medical_review" href="/d/html/5820.html" rel="external">"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents", section on 'Laboratory tests'</a>). This recommendation is consistent with those made in an international reproductive endocrinology consensus publication [<a href="#rid89">89</a>], the American Association of Clinical Endocrinologists, and the minority position of the Androgen Excess and PCOS Society in adults with PCOS [<a href="#rid90">90,91</a>]. The prevalence of diabetes was reported to be 2 percent based on the fasting blood sugar in one series, and 8 percent when based on OGTT criteria in another series of adolescents [<a href="#rid92">92,93</a>]. In both series, almost all of the adolescents had no symptoms of diabetes. Impaired glucose tolerance suggests insulin resistance and is a risk factor for type 2 diabetes mellitus and cardiovascular disease. Thus, an abnormal OGTT has important therapeutic implications. (See  <a class="medical medical_review" href="/d/html/5853.html" rel="external">"Treatment of polycystic ovary syndrome in adolescents"</a>.)</p><p>Glucose tolerance should be monitored regularly because a substantial number of people with PCOS will experience deterioration in glucose tolerance. As an example, among 25 adolescent and young adult women followed for a mean of 34 months, the two-hour plasma glucose during an OGTT increased at an average rate of 9 mg/dL (0.5 mmol/L) per year [<a href="#rid94">94</a>]. Among the 14 women with PCOS and normal glucose tolerance at baseline, 55 percent experienced deterioration of glucose tolerance when they were retested with an OGTT. Among the 14 women with PCOS and impaired glucose tolerance at baseline, 29 percent progressed to diabetes.</p><p>Patients should also be evaluated for quality-of-life issues. These include sense of self, relationships with family and friends, and pain. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Psychological issues'</a>.)</p><p>PCOS is a risk factor for endometrial carcinoma in young people [<a href="#rid95">95</a>]. The basis of the risk is multifactorial: it is related to the endometrial hyperplasia that arises from persistent estrogen stimulation without the progesterone-induced inhibition of proliferation and differentiation to secretory endometrium that occurs after ovulation. Hyperandrogenism, insulin-resistant hyperinsulinemia, and the inflammatory changes of obesity appear to be aggravating factors for endometrial carcinoma; risk also seems related to body mass index (BMI)-independent proto-oncogenic changes in endometrial cells [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults", section on 'Endometrial cancer risk'</a>.)</p><p class="headingAnchor" id="H768363740"><span class="h1">EVALUATION OF FAMILY MEMBERS</span><span class="headingEndMark"> — </span>Parents and siblings of PCOS patients are at increased risk for metabolic syndrome and diabetes mellitus, particularly if they are obese. Screening can be accomplished by measurement of hemoglobin A1c or oral glucose tolerance testing (OGTT) in first-degree relatives of either sex. Premenopausal mothers and sisters are at risk for PCOS and should be screened for those features.</p><p>These recommendations are prompted by the high prevalence of PCOS and metabolic syndrome among immediate relatives of individuals with PCOS (see  <a class="medical medical_review" href="/d/html/5799.html" rel="external">"Etiology and pathophysiology of polycystic ovary syndrome in adolescents", section on 'Heritable traits'</a>). According to one study, approximately one-half of sisters of PCOS probands have an elevated serum testosterone level, and one-half of these (one-quarter of the total) in turn have menstrual irregularity and thus meet National Institutes of Health criteria for PCOS [<a href="#rid97">97</a>]. In another study, approximately one-quarter of sisters met the Androgen Excess and PCOS Society criteria for PCOS, having hyperandrogenism and a polycystic ovary, although menses were ovulatory [<a href="#rid98">98</a>]. The likelihood of a mother having PCOS seems similar: 22 percent in our Chicago series [<a href="#rid92">92</a>].</p><p>The prevalence of metabolic syndrome or diabetes mellitus in parents of people with PCOS is higher than in parents of people without PCOS. In our Chicago series, one-third or more of mothers and the great majority of fathers had metabolic syndrome and diabetes mellitus [<a href="#rid92">92</a>]. Notably, the diabetes was asymptomatic in one-half and was uncovered by glucose tolerance testing. Meta-analysis has demonstrated a significantly greater prevalence of insulin resistance and type 2 diabetes mellitus in the parents of PCOS patients and a trend toward insulin resistance and diabetes in siblings [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H1040865102"><span class="h1">OTHER RESOURCES</span><span class="headingEndMark"> — </span>The following online resources are available to patients with PCOS and their families:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2Fwp-content%2Fuploads%2F2014%2F10%2FPCOS-Resources-for-a-Healthier-You.pdf&amp;token=kVJoG6A%2Fde0zKYaVurhJoOl%2F3cPgXTif9uMUhUxGGvpMLnYG7P7hpO8y66v0xFO7dhEb9ARbvl6%2FbmHKqCKN5plNvMBU40TXEDl15ZDIAzJw%2F9m8R1d8utQbzT9MrPFN&amp;TOPIC_ID=94182" target="_blank">PCOS resources for a healthier you</a> – From the Center for Young Women's Health of Boston Children's Hospital [<a href="#rid100">100</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpedsendo.org%2Fpatient-resource%2Fpolycystic-ovary-syndrome%2F&amp;token=WSSYIc3cOj5Gh5gQdKxkJrdBsHpn59ZFHX9DDqXTUOeW%2BTLd9MkC%2Fpu778upUvVlJVuIdyOhe1ff%2FQrHlW2e80ZQGJg5KM8ogyQyNM0S2FU%3D&amp;TOPIC_ID=94182" target="_blank">Polycystic Ovary Syndrome: A Guide for Families</a> – From the Pediatric Endocrine Society and the American Academy of Pediatrics [<a href="#rid101">101</a>]</p><p></p><p class="headingAnchor" id="H929779191"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110097.html" rel="external">"Society guideline links: Polycystic ovary syndrome"</a> and  <a class="medical medical_society_guidelines" href="/d/html/110632.html" rel="external">"Society guideline links: Hirsutism"</a>.)</p><p class="headingAnchor" id="H768363746"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15605.html" rel="external">"Patient education: Polycystic ovary syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/2163.html" rel="external">"Patient education: Polycystic ovary syndrome (PCOS) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H768363758"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for evaluation –</strong> The evaluation for polycystic ovary syndrome (PCOS) begins with a focused clinical evaluation for the presence of hirsutism (or hirsutism equivalents, such as moderate-to-severe acne that is resistant to topical or oral antibiotic therapy) and menstrual abnormalities  (<a class="graphic graphic_table graphicRef93199" href="/d/graphic/93199.html" rel="external">table 1</a>). Some patients may present with a chief complaint of acanthosis nigricans or obesity before the more classical manifestations develop. (See <a class="local">'Indications for evaluation'</a> above and <a class="local">'History and physical examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Testing for hyperandrogenemia</strong> –<strong> </strong>The clinical evaluation is followed by laboratory testing for androgen excess with free testosterone  (<a class="graphic graphic_algorithm graphicRef117557" href="/d/graphic/117557.html" rel="external">algorithm 1</a>). If serum free testosterone levels are normal (in the absence of oral contraceptives), the diagnosis of PCOS is unlikely. However, the possibility of PCOS in an adolescent should not be fully dismissed until menses normalize and androgen levels are persistently normal. (See <a class="local">'Testing for hyperandrogenemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screening tests to detect common causes of abnormal menses</strong> – Patients with abnormal menses should also be screened for other common causes of this symptom, including tests for pregnancy, primary or central hypogonadism (follicle-stimulating hormone and luteinizing hormone), thyroid-stimulating hormone, and basic screening tests for chronic disease (complete blood count, erythrocyte sedimentation rate, and a comprehensive metabolic panel). (See <a class="local">'Screening tests to detect common causes of abnormal menses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional testing for non-PCOS causes of hyperandrogenemia</strong> – If serum levels of total or free testosterone are elevated, a focused history and physical examination should be performed to exclude other hyperandrogenic disorders; clinical guidelines recommend 17-hydroxyprogesterone (17OHP) testing at this time. Expert practice varies regarding the extent and timing of further laboratory evaluation. Some experts perform a simple screening battery of endocrine tests and ultrasonography at this stage  (<a class="graphic graphic_algorithm graphicRef85781" href="/d/graphic/85781.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef91894" href="/d/graphic/91894.html" rel="external">table 3</a>). Other experts perform the screening tests other than 17OHP only in patients with atypical features, such as Cushingoid features, galactorrhea, or virilization. (See <a class="local">'Screening tests to exclude common non-PCOS causes of hyperandrogenemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the results of the endocrine screening panel for other causes of hyperandrogenism are normal <strong>and</strong> the menstrual abnormality is persistent, the diagnosis of PCOS is confirmed with a high level of certainty  (<a class="graphic graphic_table graphicRef107842" href="/d/graphic/107842.html" rel="external">table 2</a>). Any abnormal results suggest that the hyperandrogenism is caused by a disorder other than PCOS. (See <a class="local">'Endocrine screening panel'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The primary purpose of ultrasonography is to exclude the rare but serious virilizing ovarian tumor that can mimic PCOS. Determining whether the ovaries are polycystic is not helpful for the diagnosis of PCOS, because of the high frequency of polycystic-appearing ovaries in adolescents with or without PCOS. (See <a class="local">'Ultrasonography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for further evaluation by a pediatric endocrinologist</strong> – Patients with atypical features, such as virilization, unexplained congenital or familial hyperandrogenism, or unresponsiveness to standard PCOS therapy may have a rare virilizing disorder rather than PCOS. In such cases, we suggest referral to a subspecialist for further evaluation for rare disorders mimicking PCOS, commencing with a <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> androgen-suppression test (DAST)  (<a class="graphic graphic_algorithm graphicRef65682" href="/d/graphic/65682.html" rel="external">algorithm 3</a>). (See <a class="local">'Further evaluation by endocrinology subspecialists for rare disorders mimicking PCOS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional evaluation</strong> – Once a diagnosis of PCOS has been established, it is important to discuss the potential long-term sequelae and required interventions for the disorder. These include the need for ongoing lifestyle management, as well as formal emotional support and counseling, and the possibility of future infertility and/or endometrial carcinoma. It is also important to identify and monitor for abnormal glucose tolerance, type 2 diabetes, dyslipidemia, hypertension, and sleep-disordered breathing. This is because PCOS is a risk factor for the early development of these disorders. (See <a class="local">'Additional evaluation of PCOS patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Family members</strong> –<strong> </strong>Immediate family members are also at risk for similar metabolic dysfunction, and premenopausal mothers and sisters are at risk for PCOS. (See <a class="local">'Evaluation of family members'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Ehrmann DA, Littlejohn EE. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab 2015; 100:1537.</a></li><li><a class="nounderline abstract_t">Day F, Karaderi T, Jones MR, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 2018; 14:e1007813.</a></li><li><a class="nounderline abstract_t">Rosenfield RL. Perspectives on the International Recommendations for the Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescence. J Pediatr Adolesc Gynecol 2020; 33:445.</a></li><li><a class="nounderline abstract_t">Rosenfield RL. What every physician should know about polycystic ovary syndrome. Dermatol Ther 2008; 21:354.</a></li><li><a class="nounderline abstract_t">Witchel SF, Oberfield S, Rosenfield RL, et al. The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Horm Res Paediatr 2015.</a></li><li><a class="nounderline abstract_t">Rosenfield RL. The Diagnosis of Polycystic Ovary Syndrome in Adolescents. Pediatrics 2015; 136:1154.</a></li><li><a class="nounderline abstract_t">Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm Res Paediatr 2017; 88:371.</a></li><li><a class="nounderline abstract_t">Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2023; 108:2447.</a></li><li><a class="nounderline abstract_t">Ibáñez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab 1999; 84:2691.</a></li><li><a class="nounderline abstract_t">Risal S, Pei Y, Lu H, et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. Nat Med 2019; 25:1894.</a></li><li><a class="nounderline abstract_t">Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34:677.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Mortensen M, Wroblewski K, et al. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod 2011; 26:3138.</a></li><li><a class="nounderline abstract_t">Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1233.</a></li><li><a class="nounderline abstract_t">FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:1440.</a></li><li><a class="nounderline abstract_t">Goodman NF, Cobin RH, Futterweit W, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1. Endocr Pract 2015; 21:1291.</a></li><li><a class="nounderline abstract_t">Salameh WA, Redor-Goldman MM, Clarke NJ, et al. Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria. Fertil Steril 2014; 101:1135.</a></li><li><a class="nounderline abstract_t">Tosi F, Fiers T, Kaufman JM, et al. Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2016; 101:610.</a></li><li><a class="nounderline abstract_t">Moll GW Jr, Rosenfield RL. Testosterone binding and free plasma androgen concentrations under physiological conditons: chararacterization by flow dialysis technique. J Clin Endocrinol Metab 1979; 49:730.</a></li><li class="breakAll">Rosenfield RL, Moll GW. The role of proteins in the distribution of plasma androgens and estradiol. In: Androgenization in women, Molinatti G, Martini L, James V (Eds), Raven Press, New York 1983. p.25-45.</li><li><a class="nounderline abstract_t">Pugeat M, Nader N, Hogeveen K, et al. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol Cell Endocrinol 2010; 316:53.</a></li><li><a class="nounderline abstract_t">Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72:83.</a></li><li><a class="nounderline abstract_t">Simó R, Barbosa-Desongles A, Lecube A, et al. Potential role of tumor necrosis factor-α in downregulating sex hormone-binding globulin. Diabetes 2012; 61:372.</a></li><li><a class="nounderline abstract_t">Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84:3666.</a></li><li><a class="nounderline abstract_t">Keefe CC, Goldman MM, Zhang K, et al. Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry. PLoS One 2014; 9:e93805.</a></li><li><a class="nounderline abstract_t">Fiers T, Wu F, Moghetti P, et al. Reassessing Free-Testosterone Calculation by Liquid Chromatography-Tandem Mass Spectrometry Direct Equilibrium Dialysis. J Clin Endocrinol Metab 2018; 103:2167.</a></li><li><a class="nounderline abstract_t">Auchus RJ. Steroid assays and endocrinology: best practices for basic scientists. Endocrinology 2014; 155:2049.</a></li><li><a class="nounderline abstract_t">Legro RS, Schlaff WD, Diamond MP, et al. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab 2010; 95:5305.</a></li><li><a class="nounderline abstract_t">Rosner W, Vesper H, Endocrine Society, et al. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab 2010; 95:4542.</a></li><li><a class="nounderline abstract_t">Sharma A, Kapoor E, Singh RJ, et al. Diagnostic Thresholds for Androgen-Producing Tumors or Pathologic Hyperandrogenism in Women by Use of Total Testosterone Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry. Clin Chem 2018; 64:1636.</a></li><li><a class="nounderline abstract_t">Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 1974; 39:340.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Helke JC. Small diurnal and episodic fluctuations of the plasma free testosterone level in normal women. Am J Obstet Gynecol 1974; 120:461.</a></li><li><a class="nounderline abstract_t">Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140:815.</a></li><li><a class="nounderline abstract_t">Pagán YL, Srouji SS, Jimenez Y, et al. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab 2006; 91:1309.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res 2010; 1364:186.</a></li><li><a class="nounderline abstract_t">Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci 2013; 6:168.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol 2009; 114:936.</a></li><li><a class="nounderline abstract_t">Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98:4565.</a></li><li><a class="nounderline abstract_t">Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19.</a></li><li><a class="nounderline abstract_t">Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Cohen RM, Talerman A. Lipid cell tumor of the ovary in reference to adult-onset congenital adrenal hyperplasia and polycystic ovary syndrome. A case report. J Reprod Med 1987; 32:363.</a></li><li><a class="nounderline abstract_t">CORRIGENDUM FOR "Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline". J Clin Endocrinol Metab 2019; 104:39.</a></li><li><a class="nounderline abstract_t">Sun BZ, Kangarloo T, Adams JM, et al. Healthy Post-Menarchal Adolescent Girls Demonstrate Multi-Level Reproductive Axis Immaturity. J Clin Endocrinol Metab 2019; 104:613.</a></li><li><a class="nounderline abstract_t">McNeely MJ, Soules MR. The diagnosis of luteal phase deficiency: a critical review. Fertil Steril 1988; 50:1.</a></li><li><a class="nounderline abstract_t">Elhassan YS, Idkowiak J, Smith K, et al. Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women. J Clin Endocrinol Metab 2018; 103:1214.</a></li><li><a class="nounderline abstract_t">O'Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014; 99:1027.</a></li><li><a class="nounderline abstract_t">Turcu AF, Rege J, Auchus RJ, Rainey WE. 11-Oxygenated androgens in health and disease. Nat Rev Endocrinol 2020; 16:284.</a></li><li><a class="nounderline abstract_t">Yoshida T, Matsuzaki T, Miyado M, et al. 11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome. Endocr J 2018; 65:979.</a></li><li><a class="nounderline abstract_t">Rosenfield RL. Normal and Premature Adrenarche. Endocr Rev 2021; 42:783.</a></li><li><a class="nounderline abstract_t">Glickman SP, Rosenfield RL, Bergenstal RM, Helke J. Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women. J Clin Endocrinol Metab 1982; 55:251.</a></li><li><a class="nounderline abstract_t">Filho RB, Domingues L, Naves L, et al. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol 2007; 23:267.</a></li><li><a class="nounderline abstract_t">Vilar L, Vilar CF, Lyra R, Freitas MDC. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. Neuroendocrinology 2019; 109:7.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Androulakis II, Tziveriotis K, et al. Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. Clin Endocrinol (Oxf) 2007; 67:917.</a></li><li><a class="nounderline abstract_t">Littlejohn EE, Weiss RE, Deplewski D, et al. Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. J Pediatr Endocrinol Metab 2007; 20:41.</a></li><li><a class="nounderline abstract_t">Screening and Management of the Hyperandrogenic Adolescent: ACOG Committee Opinion, Number 789. Obstet Gynecol 2019; 134:e106.</a></li><li><a class="nounderline abstract_t">Bremer AA. Polycystic ovary syndrome in the pediatric population. Metab Syndr Relat Disord 2010; 8:375.</a></li><li><a class="nounderline abstract_t">Fitzgerald S, Stamoulis C, Gooding HC, DiVasta AD. Characteristics of Adolescents with Differing Polycystic Ovary Syndrome Phenotypes. J Pediatr Adolesc Gynecol 2020; 33:697.</a></li><li><a class="nounderline abstract_t">Pascale MM, Pugeat M, Roberts M, et al. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clin Endocrinol (Oxf) 1994; 41:571.</a></li><li><a class="nounderline abstract_t">Prassopoulos V, Laspas F, Vlachou F, et al. Leydig cell tumour of the ovary localised with positron emission tomography/computed tomography. Gynecol Endocrinol 2011; 27:837.</a></li><li><a class="nounderline abstract_t">Rosenfield RL. The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum. J Pediatr Adolesc Gynecol 2015; 28:412.</a></li><li><a class="nounderline abstract_t">Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9:505.</a></li><li><a class="nounderline abstract_t">Bentzen JG, Forman JL, Johannsen TH, et al. Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab 2013; 98:1602.</a></li><li><a class="nounderline abstract_t">Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014; 20:334.</a></li><li><a class="nounderline abstract_t">Kenigsberg LE, Agarwal C, Sin S, et al. Clinical utility of magnetic resonance imaging and ultrasonography for diagnosis of polycystic ovary syndrome in adolescent girls. Fertil Steril 2015; 104:1302.</a></li><li><a class="nounderline abstract_t">Assens M, Dyre L, Henriksen LS, et al. Menstrual Pattern, Reproductive Hormones, and Transabdominal 3D Ultrasound in 317 Adolescent Girls. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Fulghesu AM, Canu E, Casula L, et al. Polycystic Ovarian Morphology in Normocyclic Non-hyperandrogenic Adolescents. J Pediatr Adolesc Gynecol 2021; 34:610.</a></li><li><a class="nounderline abstract_t">Gilligan LA, Trout AT, Schuster JG, et al. Normative values for ultrasound measurements of the female pelvic organs throughout childhood and adolescence. Pediatr Radiol 2019; 49:1042.</a></li><li><a class="nounderline abstract_t">Villarroel C, Merino PM, López P, et al. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod 2011; 26:2861.</a></li><li><a class="nounderline abstract_t">Merino PM, Villarroel C, Jesam C, et al. New Diagnostic Criteria of Polycystic Ovarian Morphology for Adolescents: Impact on Prevalence and Hormonal Profile. Horm Res Paediatr 2017; 88:401.</a></li><li><a class="nounderline abstract_t">Brown M, Park AS, Shayya RF, et al. Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and age-matched controls. J Magn Reson Imaging 2013; 38:689.</a></li><li><a class="nounderline abstract_t">Lavery GG, Walker EA, Tiganescu A, et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 2008; 93:3827.</a></li><li><a class="nounderline abstract_t">Bidet M, Bellanné-Chantelot C, Galand-Portier MB, et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009; 94:1570.</a></li><li><a class="nounderline abstract_t">Ambroziak U, Kępczyńska-Nyk A, Kuryłowicz A, et al. The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis. Clin Endocrinol (Oxf) 2016; 84:23.</a></li><li><a class="nounderline abstract_t">Carmina E, Dewailly D, Escobar-Morreale HF, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update 2017; 23:580.</a></li><li><a class="nounderline abstract_t">Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995; 16:322.</a></li><li><a class="nounderline abstract_t">Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002; 87:2611.</a></li><li><a class="nounderline abstract_t">Joehrer K, Geley S, Strasser-Wozak EM, et al. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet 1997; 6:1829.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Wroblewski K, Padmanabhan V, et al. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012; 98:242.</a></li><li><a class="nounderline abstract_t">Hart R, Doherty DA, Norman RJ, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril 2010; 94:1118.</a></li><li><a class="nounderline abstract_t">Caanen MR, Peters HE, van de Ven PM, et al. Anti-Müllerian Hormone Levels in Adolescence in Relation to Long-term Follow-up for Presence of Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2021; 106:e1084.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev 2016; 37:467.</a></li><li><a class="nounderline abstract_t">Gorsic LK, Kosova G, Werstein B, et al. Pathogenic Anti-Müllerian Hormone Variants in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2017; 102:2862.</a></li><li><a class="nounderline abstract_t">Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 2012; 97:1673.</a></li><li><a class="nounderline abstract_t">Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989; 320:559.</a></li><li><a class="nounderline abstract_t">Barnes RB, Ehrmann DA, Brigell DF, Rosenfield RL. Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency. J Clin Endocrinol Metab 1993; 76:450.</a></li><li><a class="nounderline abstract_t">Peña AS, Teede H, Hewawasam E, et al. Diagnosis experiences of adolescents with polycystic ovary syndrome: Cross-sectional study. Clin Endocrinol (Oxf) 2022; 96:62.</a></li><li><a class="nounderline abstract_t">Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93:1276.</a></li><li><a class="nounderline abstract_t">Fauser BC, Bouchard P. Uncertainty remains in women with PCOS regarding the increased incidence of cardiovascular disease later in life, despite the indisputable presence of multiple cardiovascular risk factors at a young age. J Clin Endocrinol Metab 2011; 96:3675.</a></li><li><a class="nounderline abstract_t">Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97:28.</a></li><li><a class="nounderline abstract_t">American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract 2005; 11:126.</a></li><li><a class="nounderline abstract_t">Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92:4546.</a></li><li><a class="nounderline abstract_t">Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab 2006; 91:1275.</a></li><li><a class="nounderline abstract_t">Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91:492.</a></li><li><a class="nounderline abstract_t">Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141.</a></li><li><a class="nounderline abstract_t">Farhi DC, Nosanchuk J, Silverberg SG. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 1986; 68:741.</a></li><li><a class="nounderline abstract_t">Piltonen TT, Chen J, Erikson DW, et al. Mesenchymal stem/progenitors and other endometrial cell types from women with polycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential. J Clin Endocrinol Metab 2013; 98:3765.</a></li><li><a class="nounderline abstract_t">Legro RS, Driscoll D, Strauss JF 3rd, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95:14956.</a></li><li><a class="nounderline abstract_t">Franks S, Webber LJ, Goh M, et al. Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries. J Clin Endocrinol Metab 2008; 93:3396.</a></li><li><a class="nounderline abstract_t">Yilmaz B, Vellanki P, Ata B, Yildiz BO. Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril 2018; 110:523.</a></li><li class="breakAll">Center for Young Women's Health. PCOS (polycystic ovary syndrome). Available at: https://youngwomenshealth.org/2014/02/25/polycystic-ovary-syndrome/ (Accessed on March 15, 2018).</li><li class="breakAll">Pediatric Endocrine Society and the American Academy of Pediatrics: Polycystic Ovary Syndrome: A guide for Patients and
Parents. Available at: https://www.pedsendo.org/assets/patients_families/Educational_Materials/PolycysticOvarySyndrome.pdf (Accessed on March 15, 2018).</li></ol></div><div id="topicVersionRevision">Topic 94182 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181052" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The prevalence and features of the polycystic ovary syndrome in an unselected population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25675386" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30566500" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32615268" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Perspectives on the International Recommendations for the Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18844713" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : What every physician should know about polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25833060" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Diagnosis of Polycystic Ovary Syndrome during Adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598450" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Diagnosis of Polycystic Ovary Syndrome in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29156452" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37580314" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443661" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Anovulation after precocious pubarche: early markers and time course in adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31792459" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16085166" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Polycystic ovary syndrome in adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21908468" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522147" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13892577" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical assessment of body hair growth in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26509855" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24534279" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26695861" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/573761" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Testosterone binding and free plasma androgen concentrations under physiological conditons: chararacterization by flow dialysis technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/573761" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Testosterone binding and free plasma androgen concentrations under physiological conditons: chararacterization by flow dialysis technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786070" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1898744" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22210320" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Potential role of tumor necrosis factor-αin downregulating sex hormone-binding globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10523012" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A critical evaluation of simple methods for the estimation of free testosterone in serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24713888" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29618085" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reassessing Free-Testosterone Calculation by Liquid Chromatography-Tandem Mass Spectrometry Direct Equilibrium Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24837046" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Steroid assays and endocrinology: best practices for basic scientists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826578" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926540" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Toward excellence in testosterone testing: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30068692" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnostic Thresholds for Androgen-Producing Tumors or Pathologic Hyperandrogenism in Women by Use of Total Testosterone Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4278727" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4472308" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Small diurnal and episodic fluctuations of the plasma free testosterone level in normal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7258262" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hirsutism: implications, etiology, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434454" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20816944" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24347930" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hyperprolactinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19888063" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : ACOG Practice Bulletin No. 108: Polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24151290" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14711538" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18950759" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3598985" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lipid cell tumor of the ovary in reference to adult-onset congenital adrenal hyperplasia and polycystic ovary syndrome. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30407499" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : CORRIGENDUM FOR "Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289507" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Healthy Post-Menarchal Adolescent Girls Demonstrate Multi-Level Reproductive Axis Immaturity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3289975" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The diagnosis of luteal phase deficiency: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29342266" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423344" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203405" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : 11-Oxygenated androgens in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30012903" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : 11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33788946" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Normal and Premature Adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6282921" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17558684" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Polycystic ovary syndrome and hyperprolactinemia are distinct entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30889571" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17651451" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17315528" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31568365" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Screening and Management of the Hyperandrogenic Adolescent: ACOG Committee Opinion, Number 789.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20939704" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Polycystic ovary syndrome in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32889085" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Characteristics of Adolescents with Differing Polycystic Ovary Syndrome Phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7828344" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668318" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Leydig cell tumour of the ovary localised with positron emission tomography/computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25840648" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14714587" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ultrasound assessment of the polycystic ovary: international consensus definitions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23463653" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24345633" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26354095" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical utility of magnetic resonance imaging and ultrasonography for diagnosis of polycystic ovary syndrome in adolescent girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32506132" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Menstrual Pattern, Reproductive Hormones, and Transabdominal 3D Ultrasound in 317 Adolescent Girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33571658" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Polycystic Ovarian Morphology in Normocyclic Non-hyperandrogenic Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31093723" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Normative values for ultrasound measurements of the female pelvic organs throughout childhood and adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784736" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049986" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : New Diagnostic Criteria of Polycystic Ovarian Morphology for Adolescents: Impact on Prevalence and Hormonal Profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23292744" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and age-matched controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18628520" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208730" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26331608" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28582566" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7671850" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050224" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9302260" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541936" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20060112" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33351079" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Anti-Müllerian Hormone Levels in Adolescence in Relation to Long-term Follow-up for Presence of Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27459230" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28505284" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pathogenic Anti-Müllerian Hormone Variants in Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22378815" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2521688" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381802" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34585425" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Diagnosis experiences of adolescents with polycystic ovary syndrome: Cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182456" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22143833" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Uncertainty remains in women with PCOS regarding the increased incidence of cardiovascular disease later in life, despite the indisputable presence of multiple cardiovascular risk factors at a young age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22153789" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15915567" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056778" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449341" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249280" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10333916" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3785784" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Endometrial adenocarcinoma in women under 25 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824412" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Mesenchymal stem/progenitors and other endometrial cell types from women with polycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843997" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559912" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29960703" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
